. Author manuscript; available in PMC: 2021 Dec 1.

Published in final edited form as: Curr Hematol Malig Rep. 2020 Dec;15(6):424–435. doi: 10.1007/s11899-020-00597-y

Table 2.

Previous Studies on Ph+ ALL. EFS = Event Free Survival. OS = Overall Survival. HR = Hazard Ratio. CR1 = First Complete Remission. CMR = Complete Molecular Response.

Study	ALL Subtype	Age	Overview	Results	Takeaways
Shen et al.⁴⁹	Ph+ ALL	0-18	Comparison of dasatinib to imatinib in treatment of Ph+ ALL in pediatric population	Significant improvement in 4-year EFS and OS between dasatinib vs imatinib groups: 71 % vs 48.9% (p=0.005) & 88.4% vs 69.2% (p=0.04)	Newer generation TKIs may prove more effective in treatment of Ph+ ALL when compared to first generation TKIs
Chang et al.³⁶	Ph+ ALL	18-70	Comparison of outcomes for adult Ph+ ALL patients treated with combination chemotherapy + dasatinib vs combination chemotherapy + dasatinib followed by alloSCT	Similar outcomes between the transplant and non-transplant group: 3-year OS 76% vs 71.3% (p=0.56), 3-year RFS 70.5% vs 80.1% (p=0.94)	With newer generation TKIs, routine alloSCT in CR1 may not be indicated
Jabbour et al.⁵⁰	Ph+ ALL	>18 (median 47)	Phase II trial of ponatinib + hyper-CVAD in treatment of adult Ph+ ALL	Good long-term outcomes: 83% achieved CMR, 3-year OS 76%. No improvement in survival with alloSCT: 3-year OS in transplant group vs non-transplant group was 70% vs 87%.	Ponatinib + combination chemotherapy leads to good long-term outcomes, and may avoid need for routine alloSCT in CR1
Ravandi et al.⁴²	Ph+ ALL	18-60	Outcomes of adult patients with Ph+ ALL treated with dasatinib + combination chemotherapy followed by alloSCT	3-year RFS in patients who did NOT undergo SCT in CR1 (44 pts) was 51%; 3-year RFS for those who did undergo alloSCT in CR1 was 76%; statistically significant improvement in RFS and OS for pts who underwent SCT vs no SCT (NOT randomized however)	Addition of dasatinib to chemo and alloSCT for younger patients with Ph+ ALL is feasible and efficacious. Patients fared better if they received alloSCT, however the study was not randomized and thus warrants further testing.
NCT02744768	Ph+ ALL	≥18	Outcomes of patients treated with dasatinib + blinatumomab	Initial results show a 1-year OS of 94.2%	Addition of blinatumomab to TKI therapy may allow avoidance of intensive chemotherapy